非小细胞肺癌脑转移厄洛替尼结合全脑放疗治疗的理论基础和研究进展

非小细胞肺癌（NSCLC）脑转移患者预后极差，全脑放疗（WBRT）不能同时控制颅外病灶。酪氨酸激酶抑制剂（TKI）对肺腺癌脑转移瘤患者的研究结果是令人鼓舞的，表皮生长因子受体（EGFR）突变状态与疗效相关。厄洛替尼配合全脑放疗治疗肺癌脑转移患者增敏的理论基础存在。目前，小型临床试验资料显示厄洛替尼联合全脑放疗较单纯厄洛替尼疗效更佳，且不良反应可耐受。

The theoretical foundation and research progress for erlotinib combined with whole brain radiotherapy for the treatment for non-small cell lung cancer patients with brain metastases

The prognosis of patients with brain metastases from non-small cell lung cance （NSCLC）is dismal, and whole brain radiation therapy（WBRT） cannot simultaneously control the extracranial lesions. Stud- y results of Tyrosine kinase inhibitor（TKI） for brain metastases in patients with lung cancer are encouraging,and treatment efficacy is related to EGFR mutation status. The sensitizing theoretical foundation exists in utili- zing erlotinib combined with WBRT for the treatment in brain metastases patients with lung cancer. Currently, a small clinical trial data shows that erlotinib combined with WBRT has better efficacy compared to erlotinib alone, and the toxicity can be tolerated.